METHODS OF INCREASING SARCOSINE LEVELS FOR TREATING SCHIZOPHRENIA

• US 20110034551A1
• Filed: 09/18/2008
• Published: 02/10/2011
• Est. Priority Date: 09/19/2007
• Status: Abandoned Application

• Current Assignee: BG Medicine, Inc.
• Original Assignee: BG Medicine, Inc.
• Inventors: McBurney, Robert Nicholas
• Application Number:
  US12/678,614
• Publication Number:
  US 20110034551A1
• Time in Patent Office: Days
• US Class Current: 514/533
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods for increasing sarcosine levels in a patient are provided. The methods include activating the PPARα receptor. Increasing sarcosine levels can be used, for example, as part of a treatment for schizophrenia.

Claims

1. A method of increasing sarcosine levels in a patient in need thereof, the method comprising activating peroxisome proliferator activated receptor type a (PPARα

) in the patient.

2. A method of promoting N-methyl-D-aspartate (NMDA) receptor activation in a patient in need thereof, the method comprising increasing sarcosine levels in the patient according to the method of claim 1.

3. A method of treating schizophrenia in a patient in need thereof, the method comprising promoting NMDA receptor activation in the patient according to the method of claim 2.

4. The method of claim 3, further comprising antagonizing dopamine D2 receptors in the patient.

5. The method of claim 1, comprising administering a compound selected from the group consisting of clofibrate, gemfibrozil, ciprofibrate, bezafibrate, fenofibrate, simfibrate, and clofibride, and pharmaceutically acceptable salts thereof.

6. The method of claim 2, comprising administering a compound selected from the group consisting of clofibrate, gemfibrozil, ciprofibrate, bezafibrate, fenofibrate, simfibrate, and clofibride, and pharmaceutically acceptable salts thereof.

7. The method of claim 3, comprising administering a compound selected from the group consisting of clofibrate, gemfibrozil, ciprofibrate, bezafibrate, fenofibrate, simfibrate, and clofibride, and pharmaceutically acceptable salts thereof.

8. The method of claim 4, comprising administering a compound selected from the group consisting of clofibrate, gemfibrozil, ciprofibrate, bezafibrate, fenofibrate, simfibrate, and clofibride, and pharmaceutically acceptable salts thereof.